Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion

View Full Paper
Ask AI
Bookmark
Share

Authors

SFSteven M. FoltzSKSeunghee Kim‐Schulze

Discussion

Loading...

Member takes

Overview

Clinical trial reports immunomodulatory effects of daratumumab in multiple myeloma, suggesting immune response shifts in treatment efficacy.

Key Points

  • To evaluate immunomodulatory effects of daratumumab-based therapy on patients with functional high-risk relapsed/refractory myeloma.
  • Clinical trial with fHRMM patients receiving daratumumab-based quadruplet therapy.
  • Bone marrow aspirates collected pre-treatment and after therapy cycles for immune profiling.
  • Utilized techniques like single-cell RNA sequencing and CyTOF to analyze T cell populations.
  • Identified changes in CD8 T cell populations, including an expansion of effector memory T cells after initial therapy cycles.
  • Observed significant alterations in the immune microenvironment correlating with treatment response.
  • Findings suggest potential targets for improved therapeutic strategies in myeloma.

Cite This Study

Foltz et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3c4https://doi.org/10.1182/blood-2025-3955
View Full Paper
Ask AI
Bookmark
Share